Health Care/Hospital

United Imaging Intelligence at RSNA 2025: Reshaping Medicine with AI Agents

SHANGHAI, Dec. 12, 2025 /PRNewswire/ -- Under the theme "Imaging the Individual", RSNA 2025 challenged the radiology community to push into new frontiers and close the gap between personalized care and global health disparities. This year,United Imaging Intelligence (UII), the AI-focused subsidi...

2025-12-12 22:00 3239

Global Attention: POGMENT Biomimetic Collagen "Stable Triple-Helix Breakthrough" --Unconventional and Astonishing

— LivingPhoenix Forum's 12 Conference Presentation Ignite International and Domestic Academia, Hailed by Academicians as the "iPhone Moment for Extracellular Matrix Research" CHENGDU, China, Dec. 12, 2025 /PRNewswire/ -- LivingPhoenix Regenerative Technologies has drawn widespread international ...

2025-12-12 21:46 4412

Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy

NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of RAG-18 at Peking Union Medical College Hospital (PUMCH...

2025-12-12 21:35 2775

Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)

* Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD inhibitor with IND clearance granted in 2023. * The partnership combines Insilico's generative AI ...

2025-12-12 20:00 2308

Smartee Strengthens Clinical Engagement in the DACH Region with First GS Summit in Cologne and Presence at TPAO Congress

COLOGNE, Germany, Dec. 12, 2025 /PRNewswire/ -- Smartee Denti-Technology hosted its first GS-focused clinical summit inCologne on November 27, deepening its collaboration with orthodontists across the DACH region. Although Smartee has operated inGermany for more than 2 years through its local sub...

2025-12-12 17:26 1469

Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab

HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study wi...

2025-12-12 10:31 2941

Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity

* After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly superior to those observed in the placebo group (BMI r...

2025-12-12 08:00 2203

FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial

Highlights: * FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol * This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Platform Trial * Next steps include obtaining single IRB approval, site initiations and cl...

2025-12-12 04:49 1877

Datasea Announces Breakthrough in Acoustic-Driven Brain-Computer Interface Technology

Developing Healthcare and Intelligent Interaction Through Core Acoustic Innovation BEIJING, Dec. 11, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a global technology enterprise specializing in acoustic high-tech innovations and AI multimodal digital solutions, t...

2025-12-11 22:30 1479

HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025

International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors TAIPEI, SHANGHAI, AND SAN FRANCISCO, Dec. 11, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechn...

2025-12-11 21:00 1485

OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases

* Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets in metabolic diseases * OTR Therapeut...

2025-12-11 14:00 1595

Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025

HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody) combined with chemotherapy as a first-line treatment...

2025-12-11 09:53 1221

Samsung Biologics recognized as a global leader in water security

* Company receives the highest Water Security rating in two years into participation * Recognized for exceptional leadership in environmental stewardship INCHEON, South Korea, Dec. 10, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing or...

2025-12-11 07:30 1358

DNV RECEIVES CMS APPROVAL FOR NEW AMBULATORY SURGERY CENTERS ACCREDITATION PROGRAM

New offering builds on DNV's value-driven approach to healthcare accreditation, focusing on continuous improvement, patient safety and public health outcomes HOUSTON, Dec. 10, 2025 /PRNewswire/ -- DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory...

2025-12-10 22:32 1281

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters Reinvigoration of immune system + turning cold tumors hot Preliminary ex-vivo data in HER2+ patients demonstrates immune reinvigoration and reductions...

2025-12-10 21:00 4213

Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody

SAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...

2025-12-10 08:26 1349

PhyxUp Health Leads Innovation in US Rehabilitation Market with AI-Powered Remote Therapeutic Monitoring(RTM), Launches $1M Seed Funding Round

SAN FRANCISCO, Dec. 9, 2025 /PRNewswire/ -- PhyxUp Health , an AI-driven Remote Therapeutic Monitoring (RTM) platform founded by a former physical therapist andHarvard graduate, is transforming how rehabilitation clinics operate throughoutthe United States. Built as a ...

2025-12-10 00:00 1466

BestQool Launches Christmas Campaign Crossing Into 2026 Before the Next Wave of New Product Updates

NEW YORK, Dec. 9, 2025 /PRNewswire/ -- BestQool is now giving a holiday offer to help people smoothly move into 2026 as the year comes to an end and the holidays approach. FromDecember 10, 2025, to January ...

2025-12-09 23:56 996

Neurophet Introduced Use Cases of Its AI-based Brain Imaging Analysis Solutions at the SEACURE Symposium Hosted by Nanyang Technological University in Singapore

* Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer's disease treatments * Highlighted clinical value of Neurophet AQUA AD…To accelerate efforts across healthcare institutions inSoutheast Asia SEOUL, South...

2025-12-09 22:00 1356

Medit Launches AuraVue: A Unified 3D Intraoral Scan and X-Ray Visualization Powered by Overjet AI

NEWPORT BEACH, Calif., Dec. 9, 2025 /PRNewswire/ -- Medit, a global leader in 3D intraoral scanning and digital dentistry solutions, today announced the launch of AuraVue, a next-generation visualization and consultation platform that integrates Overjet's AI technology to deliver real-time diagno...

2025-12-09 21:30 972
1234567 ... 309

Week's Top Stories